Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Clinical trial NCT05428007 · RECRUITING
Trial details
- NCT number
- NCT05428007
- Sponsor
- NYU Langone Health
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-02
- Primary completion
- 2026-08-01
- Enrollment
- 105
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.